Equitable Trust Co. Boosts Stock Holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Equitable Trust Co. raised its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 15.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,465 shares of the biopharmaceutical company’s stock after purchasing an additional 1,255 shares during the period. Equitable Trust Co.’s holdings in Regeneron Pharmaceuticals were worth $2,962,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of REGN. Altfest L J & Co. Inc. bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $538,000. Bank of Nova Scotia grew its stake in Regeneron Pharmaceuticals by 25.4% in the second quarter. Bank of Nova Scotia now owns 21,832 shares of the biopharmaceutical company’s stock valued at $6,833,000 after purchasing an additional 4,420 shares during the last quarter. KBC Group NV grew its stake in Regeneron Pharmaceuticals by 25.6% in the second quarter. KBC Group NV now owns 48,628 shares of the biopharmaceutical company’s stock valued at $15,221,000 after purchasing an additional 9,912 shares during the last quarter. Calamos Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 2.1% in the second quarter. Calamos Advisors LLC now owns 11,911 shares of the biopharmaceutical company’s stock worth $3,728,000 after acquiring an additional 248 shares in the last quarter. Finally, Gargoyle Investment Advisor L.L.C. boosted its holdings in Regeneron Pharmaceuticals by 6.8% in the second quarter. Gargoyle Investment Advisor L.L.C. now owns 1,526 shares of the biopharmaceutical company’s stock worth $478,000 after acquiring an additional 97 shares in the last quarter. Hedge funds and other institutional investors own 66.54% of the company’s stock.

In other news, major shareholder Sanofi sold 172,904 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $281.15, for a total value of $48,611,959.60. 11.84% of the stock is owned by insiders.



Shares of NASDAQ:REGN traded down $1.14 during midday trading on Wednesday, reaching $288.57. The company’s stock had a trading volume of 14,099 shares, compared to its average volume of 647,314. The firm has a market cap of $31.73 billion, a price-to-earnings ratio of 14.57, a price-to-earnings-growth ratio of 1.35 and a beta of 1.13. The company has a quick ratio of 3.11, a current ratio of 3.88 and a debt-to-equity ratio of 0.07. Regeneron Pharmaceuticals Inc has a 1 year low of $271.57 and a 1 year high of $442.00. The business has a 50 day moving average price of $292.02 and a 200 day moving average price of $326.19.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $5.29 EPS for the quarter, beating the Zacks’ consensus estimate of $4.60 by $0.69. The business had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.80 billion. Regeneron Pharmaceuticals had a return on equity of 25.79% and a net margin of 28.59%. The business’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.45 earnings per share. Sell-side analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.22 earnings per share for the current fiscal year.

Several equities analysts have weighed in on REGN shares. Robert W. Baird raised Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $410.00 price target for the company in a research report on Wednesday, August 7th. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals to $344.00 and set a “market perform” rating for the company in a report on Wednesday, August 7th. TheStreet cut Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Wednesday, June 5th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, June 21st. Finally, Argus downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 18th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $396.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: Margin

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.